
Real-World Data Support Cemiplimab Efficacy in Advanced NSCLC
In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.
At the
Following the meeting, Corral Jaime shared additional insights with The American Journal of Managed Care® (AJMC®) about the poster, which featured findings from CEMI-LUNG (
Cemiplimab
In an email interview, Corral Jaime explained the study’s objectives and highlighted key findings on the real-world effectiveness and safety of cemiplimab in this patient population.1 He also discussed how clinicians should interpret the findings and how future data from the ongoing study may help inform treatment decisions for patients with advanced NSCLC.
This transcript has been lightly edited for clarity.
AJMC: What prompted CEMI-LUNG's evaluation of cemiplimab monotherapy in a real-world population of patients with advanced NSCLC?
Corral Jaime: CEMI-LUNG was designed to address an important evidence gap: understanding how cemiplimab performs in routine clinical practice, beyond the highly selected populations enrolled in clinical trials. Although EMPOWER-Lung 1 (
AJMC: CEMI-LUNG was designed to evaluate cemiplimab in a more diverse patient population than those typically enrolled in clinical trials. What were some of the most notable characteristics of the patients included in this interim analysis, and how do they compare with the EMPOWER-Lung 1 trial population?
Corral Jaime: One of the most relevant findings was the inclusion of an older, less clinically selected population. The median age was 72 years; 81.5% of patients were aged 65 years or older, and 13.7% had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher. Furthermore, 80.6% had stage IV disease and 73.9% had non-squamous histology.
These characteristics illustrate the broader clinical profile captured by CEMI-LUNG compared with EMPOWER-Lung 1, particularly regarding age and performance status, providing valuable information on the use of cemiplimab in patients who are frequently underrepresented in randomized trials.
AJMC: The study reported a median progression-free survival (PFS) of 7.6 months, while median overall survival (OS) had not yet been reached. How would you interpret these findings, particularly given the relatively short median follow-up of 5.9 months?
Corral Jaime: These findings are encouraging and consistent with the efficacy previously demonstrated in EMPOWER-Lung 1. A median PFS of 7.6 months supports the effectiveness of cemiplimab in routine clinical practice, while the fact that median OS had not been reached is particularly encouraging.
However, these results must be interpreted in the context of the relatively short median follow-up of 5.9 months. The OS data are still immature, and longer follow-up will be essential to characterize the durability of clinical benefit and establish more robust survival estimates. Overall, these preliminary findings support the translation of clinical trial results into everyday clinical practice.
AJMC: The objective response rate (ORR) was 37.4% overall and 51.6% when patients who could not be evaluated for response were excluded. How should clinicians interpret these figures? What accounts for the number of patients without an assessable response?
Corral Jaime: The overall ORR of 37.4% reflects the response rate in the entire study population and is therefore the most conservative estimate of treatment activity. When patients without an assessable response are excluded, the ORR increases to 51.6%, providing a complementary perspective on efficacy among evaluable patients.
The distinction is important in real-world studies, where not all patients undergo post-baseline radiological assessment. In CEMI-LUNG, patients classified as non-evaluable had no post-baseline disease assessment. This may reflect the challenges of routine clinical practice, including early treatment discontinuation, clinical deterioration, or other reasons preventing scheduled imaging. These figures should therefore be interpreted together, rather than considering the higher ORR in evaluable patients in isolation.
AJMC: Regarding safety, 34.1% of patients experienced treatment-related adverse events, and 9.5% experienced grade 3 or higher events. How did the safety findings compare with the clinical trial experience? Were there any notable differences in the real-world setting?
Corral Jaime: Overall, the safety profile was consistent with the established experience of cemiplimab monotherapy in EMPOWER-Lung 1, with no unexpected safety signals emerging from this interim analysis.
Treatment-related adverse events were reported in 34.1% of patients, including grade 3 or higher events in 9.5%. Importantly, these findings are reassuring considering the broader clinical profile of the real-world population, particularly the older age and higher proportion of patients with ECOG performance status of 2 or greater.
These results support the feasibility of administering cemiplimab in routine clinical practice, although continued monitoring is essential, particularly in more vulnerable patients.
AJMC: Looking ahead, what additional outcomes or patient subgroups will be particularly important to evaluate, and how might these findings inform treatment decisions for patients with advanced NSCLC?
Corral Jaime: Longer follow-up will be essential to better characterize overall survival, duration of response, and the long-term safety profile. It will also be important to examine outcomes across clinically relevant subgroups, particularly older patients, those with ECOG performance status of 2 or greater, and patients with specific metastatic sites or comorbidities.
Another important aspect will be the analysis of the cemiplimab plus chemotherapy cohort, which may help clarify the role of different treatment strategies in routine clinical practice.
Importantly, treatment selection should not rely exclusively on PD-L1 expression. The recently reported phase 3 PERSEE trial (
Taken together, these findings reinforce the importance of individualizing first-line treatment. While immunotherapy monotherapy remains a valid option for appropriately selected patients, chemoimmunotherapy should be an important consideration, even in patients with high PD-L1 expression, particularly when rapid and more reliable disease control is a clinical priority.
References
- Corral Jaime J, Bironzo P, Mascaux C, et al. CEMI-LUNG, a European-based observational study to assess cemiplimab real world effectiveness and safety in patients with advanced non-small cell lung cancer. Presented at: ESMO 2026 Congress; October 23-27, 2026; Madrid, Spain.
https://oncologypro.esmo.org/congress-resources/esmo-congress-2026?presentation=cemi_lung__a_european_based_observational_study_to - McNulty R. FDA approves cemiplimab for first-line advanced NSCLC with PD-L1 expression. AJMC. February 22, 2021. Accessed November 17, 2026.
https://www.ajmc.com/view/fda-approves-cemiplimab-for-first-line-advanced-nsclc-with-pd-l1-expression - Inserro A. FDA approves cemiplimab plus chemotherapy as first-line NSCLC treatment. AJMC. November 8, 2022. Accessed November 17, 2026.
https://www.ajmc.com/view/fda-approves-cemiplimab-plus-chemotherapy-as-first-line-nsclc-treatment
Related to this article








